Delayed LGI1 seropositivity in voltage-gated potassium channel (VGKC)-complex antibody limbic encephalitis

BMJ Case Rep. 2017 Apr 20:2017:bcr2016218893. doi: 10.1136/bcr-2016-218893.

Abstract

We utilise a clinical case to highlight why exclusion of voltage-gated potassium channel (VGKC)-complex autoantibody testing in serological evaluation of patients may delay or miss the diagnosis. A 68-year-old man presented with increasing involuntary movements consistent with faciobrachial dystonic seizures (FBDS). Initial evaluation demonstrated VGKC antibody seropositivity with leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) seronegativity. Aggressive immunotherapy with methylprednisolone and plasmapheresis was started early in the course of his presentation. Following treatment with immunotherapy, the patient demonstrated clinical improvement. Repeat serum evaluation 4 months posthospitalisation remained seropositive for VGKC-complex antibodies, with development of LGI1 autoantibody seropositivity. VGKC-complex and LGI1 antibodies remained positive 12 months posthospitalisation. Our findings suggest that clinical symptoms can predate the detection of the antibody. We conclude that when suspicion for autoimmune encephalitis is high in the setting of VGKC autoantibody positivity, regardless of LGI1 or CASPR2 seropositivity, early immunotherapy and repeat testing should be considered.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Humans
  • Immunotherapy
  • Intracellular Signaling Peptides and Proteins
  • Limbic Encephalitis / drug therapy*
  • Limbic Encephalitis / immunology
  • Male
  • Methylprednisolone / therapeutic use*
  • Potassium Channels, Voltage-Gated / immunology*
  • Proteins / metabolism*
  • Treatment Outcome

Substances

  • Intracellular Signaling Peptides and Proteins
  • LGI1 protein, human
  • Potassium Channels, Voltage-Gated
  • Proteins
  • Methylprednisolone